Preferential Ebola virus glycoprotein recognition 16–17 years after Bundibugyo virus infection

Authors:

Abstract
The re-emergence of Bundibugyo virus (BDBV), for which no licensed vaccine is available, has created an urgent need for human immunological evidence to inform evaluation of existing filovirus countermeasures. We measured IgG binding to BDBV, Ebola virus (EBOV)-Mayinga and Sudan virus (SUDV)-Gulu and SUDV-Boniface glycoproteins in 40 PCR-confirmed BDBV survivors sampled 16–17 years after infection. BDBV-specific IgG was detected in 22/40 participants (55.0%), while heterologous recognition was most frequent for EBOV-Mayinga (23/40, 57.5%), compared with SUDV-Gulu (5/40, 12.5%) and SUDV-Boniface (3/40, 7.5%). BDBV and EBOV-Mayinga responses were strongly correlated (Spearman ρ = 0.90), with recognition of both glycoproteins in 20/40 participants (50.0%). In 21 participants with detectable binding, EBOV-Mayinga endpoint titres were significantly higher than BDBV titres and remained positively correlated. These findings support functional evaluation of EBOV-based and broadly reactive filovirus countermeasures for potential relevance to BDBV.

This publication has 27 references indexed in Scilit: